• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

比较谷氨酰胺酶和癌抗原 125 用于鉴别良恶性卵巢肿瘤。

Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors.

机构信息

Department of Obstetrics and Gynecology, Faculty of Medicine, Dr. Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia.

Economics and Business School, Telkom University, Bandung, Indonesia.

出版信息

Clin Transl Sci. 2023 Nov;16(11):2144-2152. doi: 10.1111/cts.13603. Epub 2023 Aug 7.

DOI:10.1111/cts.13603
PMID:37526308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10651661/
Abstract

Increasing demand for glutaminase (GLS) due to high rates of glutamine metabolism is considered one of the hallmarks of malignancy. In parallel, cancer antigen 125 (CA-125) is a commonly used ovarian tumor marker. This study aimed to compare the roles of GLS and CA-125 in distinguishing between benign and malignant ovarian tumors. The research was conducted as a comparative study, enrolling 156 patients with ovarian tumors. Preoperative serum CA-125 and GLS levels were analyzed to evaluate their effectiveness in distinguishing between benign and malignant ovarian tumors. The results revealed that the mean levels of CA-125 and GLS were significantly higher in malignant ovarian tumors compared with benign ones (389.54 ± 494.320 vs. 193.15 ± 529.932 (U/mL) and 17.37 ± 12.156 vs. 7.48 ± 4.095 (μg/mL), respectively). The CA-125 and GLS cutoff points of 108.2 U/mL and 18.32 μg/mL, respectively, were associated with malignant ovarian tumors. Multivariate analyses showed that GLS had higher predictive capabilities compared with CA-125 (odds ratio 9.4 vs. 2.1). The accuracy of using GLS combined with CA-125 was higher than using CA-125 alone (73.1% vs. 68.8%). In conclusion, higher levels of CA-125 and GLS are associated with malignant ovarian tumors. GLS outperforms CA-125 in distinguishing between benign and malignant ovarian tumors. The combination of GLS and CA-125 demonstrated improved accuracy for distinguishing benign and malignant ovarian tumors when compared with using CA-125 alone.

摘要

由于谷氨酰胺代谢率高，对谷氨酰胺酶（GLS）的需求不断增加，被认为是恶性肿瘤的特征之一。与此同时，癌抗原 125（CA-125）是一种常用的卵巢肿瘤标志物。本研究旨在比较 GLS 和 CA-125 在鉴别良恶性卵巢肿瘤中的作用。该研究是一项比较研究，共纳入 156 例卵巢肿瘤患者。分析术前血清 CA-125 和 GLS 水平，以评估其在鉴别良恶性卵巢肿瘤中的有效性。结果显示，恶性卵巢肿瘤患者血清 CA-125 和 GLS 水平明显高于良性卵巢肿瘤患者（389.54±494.320 vs. 193.15±529.932（U/mL）和 17.37±12.156 vs. 7.48±4.095（μg/mL））。CA-125 和 GLS 的截断值分别为 108.2 U/mL 和 18.32 μg/mL，与恶性卵巢肿瘤相关。多变量分析显示，GLS 比 CA-125 具有更高的预测能力（比值比 9.4 比 2.1）。GLS 联合 CA-125 的准确率高于单独使用 CA-125（73.1%比 68.8%）。综上所述，CA-125 和 GLS 水平升高与恶性卵巢肿瘤有关。GLS 在鉴别良恶性卵巢肿瘤方面优于 CA-125。与单独使用 CA-125 相比，GLS 联合 CA-125 可提高鉴别良恶性卵巢肿瘤的准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e53/10651661/d80493aec5f9/CTS-16-2144-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e53/10651661/80220876bb87/CTS-16-2144-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e53/10651661/d3435b919622/CTS-16-2144-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e53/10651661/d80493aec5f9/CTS-16-2144-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e53/10651661/80220876bb87/CTS-16-2144-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e53/10651661/d3435b919622/CTS-16-2144-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e53/10651661/d80493aec5f9/CTS-16-2144-g002.jpg

相似文献

1
Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors.比较谷氨酰胺酶和癌抗原 125 用于鉴别良恶性卵巢肿瘤。
Clin Transl Sci. 2023 Nov;16(11):2144-2152. doi: 10.1111/cts.13603. Epub 2023 Aug 7.
2
Nomogram development for predicting ovarian tumor malignancy using inflammatory biomarker and CA-125.基于炎症生物标志物和 CA-125 预测卵巢肿瘤恶性程度的列线图的建立。
Sci Rep. 2024 Jul 9;14(1):15790. doi: 10.1038/s41598-024-66509-9.
3
The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers.CA-125、谷胱甘肽合成酶（GLS）和脂肪酸合酶（FASN）在预测上皮性卵巢癌肿瘤细胞减灭术效果中的作用
BMC Res Notes. 2020 Jul 22;13(1):346. doi: 10.1186/s13104-020-05188-x.
4
Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.CA125、人附睾蛋白 4 和 CA72-4 水平及卵巢恶性肿瘤风险算法值在韩国有和无子宫内膜异位症的卵巢肿瘤患者中的临床应用。
Ann Lab Med. 2020 Jan;40(1):40-47. doi: 10.3343/alm.2020.40.1.40.
5
Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.基于血浆氨基酸谱的指标与CA125在诊断上皮性卵巢癌及交界性恶性肿瘤中的比较
Int J Clin Oncol. 2017 Feb;22(1):118-125. doi: 10.1007/s10147-016-1035-4. Epub 2016 Sep 13.
6
[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].[血清人附睾分泌蛋白4及CA125检测在卵巢恶性肿瘤诊断中的价值]
Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6.
7
Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.评估血清CA-125、CA15-3、CA-19-9、癌胚抗原和甲胎蛋白水平对于鉴别附件肿块良恶性的重要性以及不同检测组合对诊断准确性的贡献。
Eur J Gynaecol Oncol. 2013;34(6):540-4.
8
Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.利用彩色和脉冲多普勒超声以及血清CA - 125、CA - 19.9、CA - 72.4和血管内皮生长因子测量对良性和恶性卵巢肿瘤血管生成的研究。
Ann Univ Mariae Curie Sklodowska Med. 2002;57(1):113-31.
9
Serum neopterin levels in ovarian tumors.
Int J Gynaecol Obstet. 1995 Dec;51(3):229-34. doi: 10.1016/0020-7292(95)80010-7.
10
Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.超声特征提高卵巢癌预测因子鉴别良恶性卵巢肿瘤的诊断性能。
Curr Med Sci. 2020 Feb;40(1):184-191. doi: 10.1007/s11596-020-2163-7. Epub 2020 Mar 13.

引用本文的文献

1
Nomogram development for predicting ovarian tumor malignancy using inflammatory biomarker and CA-125.基于炎症生物标志物和 CA-125 预测卵巢肿瘤恶性程度的列线图的建立。
Sci Rep. 2024 Jul 9;14(1):15790. doi: 10.1038/s41598-024-66509-9.

本文引用的文献

1
The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers.CA-125、谷胱甘肽合成酶（GLS）和脂肪酸合酶（FASN）在预测上皮性卵巢癌肿瘤细胞减灭术效果中的作用
BMC Res Notes. 2020 Jul 22;13(1):346. doi: 10.1186/s13104-020-05188-x.
2
The role of glutaminase in cancer.谷氨酰胺酶在癌症中的作用。
Histopathology. 2020 Mar;76(4):498-508. doi: 10.1111/his.14014. Epub 2020 Feb 18.
3
ACOG Committee Opinion No. 754: The Utility of and Indications for Routine Pelvic Examination.美国妇产科医师学会委员会意见 No.754：常规骨盆检查的实用性和适应证。
Obstet Gynecol. 2018 Oct;132(4):e174-e180. doi: 10.1097/AOG.0000000000002895.
4
Altered glutamine metabolism in platinum resistant ovarian cancer.铂耐药卵巢癌中谷氨酰胺代谢的改变
Oncotarget. 2016 Jul 5;7(27):41637-41649. doi: 10.18632/oncotarget.9317.
5
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.癌症生物标志物在上皮性卵巢癌中的临床应用：欧洲肿瘤标志物小组的更新指南
Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586.
6
Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway.谷氨酰胺通过mTOR/S6信号通路促进卵巢癌细胞增殖。
Endocr Relat Cancer. 2015 Aug;22(4):577-91. doi: 10.1530/ERC-15-0192. Epub 2015 Jun 4.
7
Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo.基于谷氨酰胺的正电子发射断层扫描（PET）成像有助于在体内增强对胶质瘤的代谢评估。
Sci Transl Med. 2015 Feb 11;7(274):274ra17. doi: 10.1126/scitranslmed.aaa1009.
8
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.代谢向谷氨酰胺的转变调节卵巢癌的肿瘤生长、侵袭和生物能量学。
Mol Syst Biol. 2014 May 5;10(5):728. doi: 10.1002/msb.20134892.
9
Expression of glutaminase is upregulated in colorectal cancer and of clinical significance.谷氨酰胺酶在结直肠癌中表达上调且具有临床意义。
Int J Clin Exp Pathol. 2014 Feb 15;7(3):1093-100. eCollection 2014.
10
Transvaginal ultrasonography in ovarian cancer screening: current perspectives.经阴道超声检查在卵巢癌筛查中的应用现状
Int J Womens Health. 2013 Dec 20;6:25-33. doi: 10.2147/IJWH.S38347.